(S,R,S)-AHPC-C1-Br is a high-purity E3 ligase ligand-linker conjugate designed for advanced PROTAC (Proteolysis Targeting Chimera) research and drug development. As a derivative of the well-characterized VHL E3 ligase ligand (AHPC), this conjugate incorporates a tailored C1-length linker terminated with a reactive bromide group, allowing seamless attachment to target-binding warheads. (S,R,S)-AHPC-C1-Br is ideal for constructing customized PROTACs that harness the ubiquitin-proteasome system to induce selective degradation of disease-related proteins. Its design ensures robust E3 ligase recruitment, efficient linker flexibility, and versatile conjugation capabilities. Researchers can use this compound in structure-activity relationship studies, target validation, and hit-to-lead optimization. Widely used in the generation of next-generation therapeutics, (S,R,S)-AHPC-C1-Br facilitates breakthroughs in oncology, neurodegeneration, and beyond by accelerating the development of protein degraders.
Structure of 2379404-33-6
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
(S,R,S)-AHPC-C1-Br is a specialized E3 ligase ligand-linker conjugate widely utilized in the development of PROTAC (Proteolysis Targeting Chimera) molecules. This compound is designed to bind the von Hippel-Lindau (VHL) E3 ligase, which plays a pivotal role in targeted protein degradation technologies for both research and drug discovery.
Mechanism
(S,R,S)-AHPC-C1-Br functions as a modular component in PROTAC design by harnessing its high affinity for the VHL E3 ligase. The AHPC moiety acts as a VHL ligand, while the C1-branched linker provides an adaptable attachment point for heterobifunctional conjugation. When incorporated into a PROTAC, this conjugate bridges the E3 ligase and a target protein via a custom-designed warhead. This proximity induces ubiquitination of the target protein, ultimately leading to its recognition and degradation by the proteasome.
Applications
(S,R,S)-AHPC-C1-Br is instrumental in the rational design and synthesis of VHL-based PROTACs for the study and therapeutic targeting of disease-relevant proteins. Its applications include the creation of protein degraders for cancer research, validation of disease targets, and the development of next-generation targeted therapies. This conjugate is also valuable in constructing custom PROTAC libraries and advancing small molecule-induced protein degradation strategies in both academic and pharmaceutical industry settings.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.